|
Citation
|
Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Tiu A, Cheungpasitporn W. QJM 2019; 112(2): 115-121. |
|
Affiliation
|
Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Mississippi, USA. |
|
Abstract
|
BACKGROUND: Fall prevention among older adults is a worldwide public health advocacy because of negative consequences of fall. Recent studies have shown that proton pump inhibitors (PPIs) increase the risk of fall. PPIs are among the widely prescribed medications oftentimes without clear indications. Concerns for safety of long-term use of PPIs have been raised by numerous studies.
METHODS: A systematic review was conducted in MEDLINE and EMBASE databases from inception through March 2018 to identify studies that assessed the association between the use of PPIs and the risk of fall. Effect estimates from the individual study were extracted and combined using random-effect, generic inverse variance method of DerSimonian and Laird.
RESULTS: Eight observational studies with a total of 367,068 patients were enrolled. There was a significant association between the use of PPIs and the risk of fall with the pooled OR of 1.27 (95% CI, 1.07-1.50). Meta-regression showed significant positive correlations between risk of fall in patients using PPIs and year of study (slopes = +0.25, p <0.001). The data on the risk of fall in patients using H2 receptor antagonists (H2RAs) were limited in 3 studies. The pooled OR of fall in patients using H2RAs was 0.95 (95% CI, 0.75-1.20).
CONCLUSIONS: We demonstrate a significant association between the use of PPIs and increased risk of fall. There is a significant positive correlation between the risk of fall in patients using PPIs and year of study. In addition, there is potentially higher risk of fall among PPIs users over time.
Language: en |